{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:05Z","timestamp":1792787825006,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["260 663"],"award-info":[{"award-number":["260 663"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MH CZ - DRO","award":["UHHK, 00179906"],"award-info":[{"award-number":["UHHK, 00179906"]}]},{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU21-02-00135"],"award-info":[{"award-number":["NU21-02-00135"]}],"id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union","award":["CZ.02.01.01\/00\/22_008\/0004607"],"award-info":[{"award-number":["CZ.02.01.01\/00\/22_008\/0004607"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Older patients often suffer from multiple disorders and are hence frequently burdened by polypharmacy. Prevention of cardiovascular events using antiplatelet drugs might be indicated among older populations, but there are no studies assessing platelet function in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using impedance aggregometry, we compared platelet reactivity to 7 aggregation inducers between a group of 44 polymorbid older patients aged 78\u2009+\u2009years (PP), and 50 generally healthy younger controls (median age, 44\u00a0years). None of the subjects were treated with antiplatelet therapy. We also examined their response to antiplatelet drugs (acetylsalicylic acid, ticagrelor, vorapaxar) and an experimental compound, 4-methylcatechol, a small polyphenol metabolite of many natural polyphenolic compounds. Data analysis was performed in the whole group as well as after removing or splitting the groups based on concomitantly administered drugs. Linear mixed-effects modelling was used to investigate the impact of both drugs and comorbidities on the obtained results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A clinically achievable concentration of ASA (30\u00a0\u00b5M) failed to block platelet aggregation when arachidonic acid was used as an inducer, but the response to ticagrelor, vorapaxar, and 4-methylcatechol with relevant inducers was significant. However, the sensitivity to ticagrelor and vorapaxar was lower in PP when compared to healthy controls. The analysis also confirmed similar activity for 4-methylcatechol, but lower activity for acetylsalicylic acid in our PP. Further analyses excluding specific drugs did not significantly alter these outcomes. Inflammatory markers and the presence of type 2 diabetes mellitus were significant predictors of platelet reactivity while basic blood parameter data had no clear impact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>ex vivo<\/jats:italic>\n                      response of platelets from PP to the standard antiplatelet drugs was lower. In contrast, they responded well to 4-methylcatechol.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12877-026-07945-2","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:55:56Z","timestamp":1784296556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Platelet reactivity in polymorbid older patients and the effect of 4-methylcatechol"],"prefix":"10.1186","volume":"26","author":[{"given":"Marcel","family":"Hrub\u0161a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luk\u00e1\u0161","family":"Kone\u010dn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Sirov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sl\u00e1vka","family":"Homolkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Carazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u0159ina","family":"Matou\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka Kujovsk\u00e1","family":"Kr\u010dmov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bernhauerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Blaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"\u0160mahelov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6076-6900","authenticated-orcid":false,"given":"P\u0159emysl","family":"Mlad\u011bnka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"1","key":"7945_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41514-024-00148-2","volume":"10","author":"CH Jones","year":"2024","unstructured":"Jones CH, Dolsten M. Healthcare on the brink: navigating the challenges of an aging society in the United States. npj Aging. 2024;10(1):22.","journal-title":"npj Aging."},{"key":"7945_CR2","doi-asserted-by":"publisher","first-page":"100518","DOI":"10.1016\/j.jeoa.2024.100518","volume":"29","author":"M Kallestrup-Lamb","year":"2024","unstructured":"Kallestrup-Lamb M, Marin AOK, Menon S, S\u00f8gaard J. Aging populations and expenditures on health. J Econ Ageing. 2024;29:100518.","journal-title":"J Econ Ageing"},{"issue":"2","key":"7945_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/03602530902722679","volume":"41","author":"U Klotz","year":"2009","unstructured":"Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67\u201376.","journal-title":"Drug Metab Rev"},{"issue":"3","key":"7945_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40262-024-01466-0","volume":"64","author":"NN Ngcobo","year":"2025","unstructured":"Ngcobo NN. Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review. Clin Pharmacokinet. 2025;64(3):335\u201367.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"7945_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12872-025-04676-x","volume":"25","author":"X Zhang","year":"2025","unstructured":"Zhang X, Gu X, Xu Y, Wang X, Weng F, Wen Y, et al. Prevalence and clustering of modifiable cardiovascular disease risk factors among elderly adults in Yuexiu district, Guangzhou City, China: a cross sectional study. BMC Cardiovasc Disord. 2025;25(1):237.","journal-title":"BMC Cardiovasc Disord"},{"issue":"22","key":"7945_CR6","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.jacc.2025.04.002","volume":"85","author":"B Bikdeli","year":"2025","unstructured":"Bikdeli B, Ujueta F, Rashedi S, Talasaz Azita H, Kadakia Kushal T, Lopes Renato D, et al. Antiplatelet and anticoagulant therapy in the 2025 ACC\/AHA guideline for acute coronary syndromes. JACC. 2025;85(22):2074\u20138.","journal-title":"JACC"},{"issue":"1","key":"7945_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/ejhpharm-2019-002111","volume":"28","author":"LM de Oliveira","year":"2021","unstructured":"de Oliveira LM, Diel J, Nunes A, da Silva Dal Pizzol T. Prevalence of drug interactions in hospitalised elderly patients: a systematic review. Eur J Hosp Pharm. 2021;28(1):4\u20139.","journal-title":"Eur J Hosp Pharm."},{"issue":"2","key":"7945_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11096-017-0439-1","volume":"39","author":"S S\u00e1nchez-Fidalgo","year":"2017","unstructured":"S\u00e1nchez-Fidalgo S, Guzm\u00e1n-Ramos MI, Galv\u00e1n-Banqueri M, Bernabeu-Wittel M, Santos-Ramos B. Prevalence of drug interactions in elderly patients with multimorbidity in primary care. Int J Clin Pharm. 2017;39(2):343\u201353.","journal-title":"Int J Clin Pharm"},{"key":"7945_CR9","doi-asserted-by":"publisher","first-page":"102272","DOI":"10.1016\/j.molmet.2025.102272","volume":"102","author":"S Alqudah","year":"2025","unstructured":"Alqudah S, DeLucia B, Osborn LJ, Markley RL, Bobba V, Preston SM, et al. The diet-derived gut microbial metabolite 3-phenylpropionic acid reverses insulin resistance and obesity-associated metabolic dysfunction. Mol Metab. 2025;102:102272.","journal-title":"Mol Metab."},{"issue":"1","key":"7945_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1186\/s12866-025-04170-6","volume":"25","author":"S Shah","year":"2025","unstructured":"Shah S, Mu C, Shen-Tu G, Rohmann N, Schlicht K, Laudes M, et al. Influence of dietary components on the gut microbiota of middle-aged adults: the gut-Mediterranean connection. BMC Microbiol. 2025;25(1):573.","journal-title":"BMC Microbiol"},{"issue":"22","key":"7945_CR11","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.3390\/nu14224798","volume":"14","author":"M Hrub\u0161a","year":"2022","unstructured":"Hrub\u0161a M, Kone\u010dn\u00fd L, Pacl\u00edkov\u00e1 M, Parvin MS, Sko\u0159epa P, Musil F, et al. The antiplatelet effect of 4-methylcatechol in a real population sample and determination of the mechanism of action. Nutrients. 2022;14(22):4798.","journal-title":"Nutrients"},{"issue":"8","key":"7945_CR12","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3390\/nu15081842","volume":"15","author":"L Kone\u010dn\u00fd","year":"2023","unstructured":"Kone\u010dn\u00fd L, Hrub\u0161a M, Karl\u00ed\u010dkov\u00e1 J, Carazo A, Javorsk\u00e1 L, Matou\u0161ov\u00e1 K, et al. The effect of 4-Methylcatechol on platelets in familial hypercholesterolemic patients treated with lipid apheresis and\/or proprotein convertase Subtilisin Kexin 9 monoclonal antibodies. Nutrients. 2023;15(8):1842.","journal-title":"Nutrients"},{"issue":"1","key":"7945_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12933-025-02891-6","volume":"24","author":"M Pacl\u00edkov\u00e1","year":"2025","unstructured":"Pacl\u00edkov\u00e1 M, Kone\u010dn\u00fd L, Carazo A, Matou\u0161ov\u00e1 K, Kr\u010dmov\u00e1 LK, Blaha V, et al. Acetylsalicylic acid and vorapaxar are less active, while 4-methylcatechol is more active, in type 1 diabetic patients compared to healthy controls. Cardiovasc Diabetol. 2025;24(1):323.","journal-title":"Cardiovasc Diabetol"},{"key":"7945_CR14","unstructured":"Diagnostics R. Multiplate\u00ae analyzer User Guide: Roche Diagnostics; 2024. Available from: https:\/\/elabdoc-prod.roche.com\/eLD\/api\/downloads\/b206c146-dee3-ef11-2d91-005056a71a5d?countryIsoCode=gb. Cited 2026 1.6.2026."},{"issue":"3","key":"7945_CR15","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.talanta.2011.06.027","volume":"85","author":"L Krcmova","year":"2011","unstructured":"Krcmova L, Solichova D, Melichar B, Kasparova M, Plisek J, Sobotka L, et al. Determination of neopterin, kynurenine, tryptophan and creatinine in human serum by high throuput HPLC. Talanta. 2011;85(3):1466\u201371.","journal-title":"Talanta"},{"key":"7945_CR16","volume-title":"R: a language and environment for statistical computing","author":"Team RC","year":"2023","unstructured":"Team RC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2023."},{"issue":"2","key":"7945_CR17","first-page":"103","volume":"16","author":"R De Rosa","year":"2019","unstructured":"De Rosa R, Piscione F, Galasso G, De Servi S, Savonitto S. Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes. J Geriatr Cardiol. 2019;16(2):103\u201313.","journal-title":"J Geriatr Cardiol"},{"issue":"10","key":"7945_CR18","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3390\/medicina61101730","volume":"61","author":"SH Kang","year":"2025","unstructured":"Kang SH, Lee J, Kim JH, Jang Y. Comparative effectiveness of clopidogrel versus aspirin for primary prevention in high-risk patients with type 2 diabetes: a nationwide propensity score\u2013matched cohort study. Medicina (B Aires). 2025;61(10):1730.","journal-title":"Medicina (B Aires)"},{"issue":"2","key":"7945_CR19","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1097\/JS9.0000000000003667","volume":"112","author":"LC Li","year":"2025","unstructured":"Li LC, Zhang ZH, Chen MM, Xu F, Mao KL. Bleeding and antiplatelet therapies: a combined pharmacovigilance analysis of FDA adverse event reporting system database and Japanese adverse drug event report database, and the role of pharmacists. Int J Surg. 2025;112(2):3612\u201324.","journal-title":"Int J Surg."},{"issue":"19","key":"7945_CR20","doi-asserted-by":"publisher","first-page":"11317","DOI":"10.3390\/ijms231911317","volume":"23","author":"H Khan","year":"2022","unstructured":"Khan H, Kanny O, Syed MH, Qadura M. Aspirin resistance in vascular disease: a review highlighting the critical need for improved point-of-care testing and personalized therapy. Int J Mol Sci. 2022;23(19):11317.","journal-title":"Int J Mol Sci"},{"issue":"7637","key":"7945_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","volume":"336","author":"G Krasopoulos","year":"2008","unstructured":"Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336(7637):195\u20138.","journal-title":"BMJ"},{"issue":"9","key":"7945_CR22","doi-asserted-by":"publisher","first-page":"e0332323","DOI":"10.1371\/journal.pone.0332323","volume":"20","author":"B Chen","year":"2025","unstructured":"Chen B, Li Z, Zhao J, Dong H, Tong L, Dou J. Factors associated with aspirin resistance in diabetic patients: a metabolic and inflammatory profile analysis. PLoS ONE. 2025;20(9):e0332323.","journal-title":"PLoS ONE"},{"issue":"19","key":"7945_CR23","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","volume":"311","author":"AK Pedersen","year":"1984","unstructured":"Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311(19):1206\u201311.","journal-title":"N Engl J Med."},{"key":"7945_CR24","doi-asserted-by":"publisher","first-page":"107465","DOI":"10.1016\/j.vph.2025.107465","volume":"158","author":"DVS Cavalcante","year":"2025","unstructured":"Cavalcante DVS, Krishna MM, Joseph M, de Farias Santos ACF, Mendes BX, Asbeg N, et al. Indobufen versus aspirin in patients with indication for antiplatelet therapy: a systematic review and meta-analysis. Vasc Pharmacol. 2025;158:107465.","journal-title":"Vasc Pharmacol"},{"issue":"9","key":"7945_CR25","doi-asserted-by":"publisher","first-page":"e70152","DOI":"10.1111\/1753-0407.70152","volume":"17","author":"S Wu","year":"2025","unstructured":"Wu S, Xu H, Xu L, Zhang H, Cheng K, Wang X, et al. Indobufen versus aspirin plus Clopidogrel in patients after coronary stenting in patients with diabetes: a post hoc analysis of the OPTION trial. J Diabetes. 2025;17(9):e70152.","journal-title":"J Diabetes"},{"issue":"1","key":"7945_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12916-024-03374-3","volume":"22","author":"C Dai","year":"2024","unstructured":"Dai C, Liu M, Yang Z, Li Y, Zhou Y, Lu D, et al. Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry. BMC Med. 2024;22(1):148.","journal-title":"BMC Med"},{"issue":"10508","key":"7945_CR27","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","volume":"406","author":"M Valgimigli","year":"2025","unstructured":"Valgimigli M, Choi KH, Giacoppo D, Gragnano F, Kimura T, Watanabe H, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet. 2025;406(10508):1091\u2013102.","journal-title":"Lancet"},{"issue":"1","key":"7945_CR28","doi-asserted-by":"publisher","first-page":"2532454","DOI":"10.1080\/09537104.2025.2532454","volume":"36","author":"T Zhu","year":"2025","unstructured":"Zhu T, He Y, Bei Y, Mai H, Zhao L. Clopidogrel monotherapy is associated with higher mortality risk compared to aspirin: a retrospective analysis of NHANES 1999\u20132018. Platelets. 2025;36(1):2532454.","journal-title":"Platelets"},{"key":"7945_CR29","unstructured":"A Phase 2a Single Dose Study to Evaluate the Effect of BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in an Ex Vivo Thrombosis Chamber Model in Patients With Stable Coronary Artery Disease and Healthy Participants. 2021. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05093790."},{"issue":"7","key":"7945_CR30","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1021\/acs.jmedchem.3c02099","volume":"67","author":"P Chen","year":"2024","unstructured":"Chen P, Chen C, Zheng Y, Chen F, Liu Z, Ren S, et al. Discovery of 2,3-Dihydro[1,4]dioxino[2,3-g]benzofuran Derivatives as Protease Activated Receptor 4 (PAR4) antagonists with potent antiplatelet aggregation activity and low bleeding tendency. J Med Chem. 2024;67(7):5502\u201337.","journal-title":"J Med Chem"},{"issue":"4","key":"7945_CR31","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1161\/ATVBAHA.123.320448","volume":"44","author":"J Nash","year":"2024","unstructured":"Nash J, Meah MN, Whittington B, Debono S, Raftis J, Miller MR, et al. PAR4 antagonism in patients with coronary artery disease receiving antiplatelet therapies. Arterioscler Thromb Vasc Biol. 2024;44(4):987\u201396.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"7945_CR32","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1021\/acs.jmedchem.3c01986","volume":"67","author":"X Zhang","year":"2024","unstructured":"Zhang X, Jiang W, Richter JM, Bates JA, Reznik SK, Stachura S, et al. Discovery of potent and selective Quinoxaline-based Protease-Activated Receptor 4 (PAR4) antagonists for the prevention of arterial thrombosis. J Med Chem. 2024;67(5):3571\u201389.","journal-title":"J Med Chem"},{"key":"7945_CR33","doi-asserted-by":"publisher","first-page":"107500","DOI":"10.1016\/j.vph.2025.107500","volume":"159","author":"DG Brieger","year":"2025","unstructured":"Brieger DG, Rao K, Nagaraja V, Bhindi R, Allahwala UK. The use of glycoprotein IIb\/IIIa inhibitors in elective PCI - A systematic review and meta-analysis of randomised trials. Vascul Pharmacol. 2025;159:107500.","journal-title":"Vascul Pharmacol"},{"issue":"9","key":"7945_CR34","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.3174\/ajnr.A8868","volume":"46","author":"OR Gon\u00e7alves","year":"2025","unstructured":"Gon\u00e7alves OR, Santos AB, Hong A, de Almeida Monteiro G, Cardoso LJC, Ohannesian VA, et al. Comparative efficacy and safety of intravenous cangrelor versus intravenous glycoprotein IIb\/IIIa inhibitors after mechanical thrombectomy for patients with acute ischemic stroke: a systematic review and meta-analysis. AJNR Am J Neuroradiol. 2025;46(9):1838\u201343.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"7945_CR35","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1055\/s-0042-1756703","volume":"49","author":"A Carazo","year":"2023","unstructured":"Carazo A, Hrub\u0161a M, Kone\u010dn\u00fd L, Sko\u0159epa P, Pacl\u00edkov\u00e1 M, Musil F, et al. Sex-related differences in platelet aggregation: a literature review supplemented with local data from a group of generally healthy individuals. Semin Thromb Hemost. 2023;49(5):488\u2013506.","journal-title":"Semin Thromb Hemost"},{"key":"7945_CR36","doi-asserted-by":"publisher","first-page":"1615681","DOI":"10.3389\/fphar.2025.1615681","volume":"16","author":"M Zhang","year":"2025","unstructured":"Zhang M, Ni H, Lin Y, Wang K, He T, Yuan L, et al. Renal aging and its consequences: navigating the challenges of an aging population. Front Pharmacol. 2025;16:1615681.","journal-title":"Front Pharmacol."},{"issue":"1","key":"7945_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1681\/ASN.2016020154","volume":"28","author":"A Denic","year":"2017","unstructured":"Denic A, Lieske JC, Chakkera HA, Poggio ED, Alexander MP, Singh P, et al. The substantial loss of nephrons in healthy human kidneys with aging. J Am Soc Nephrol. 2017;28(1):313\u201320.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"7945_CR38","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00228-024-03704-7","volume":"80","author":"T Coppes","year":"2024","unstructured":"Coppes T, Hazen ACM, Zwart DLM, Koster ES, van Gelder T, Bouvy ML. Characteristics and preventability of medication-related admissions for acute kidney injury and dehydration in elderly patients. Eur J Clin Pharmacol. 2024;80(9):1355\u201362.","journal-title":"Eur J Clin Pharmacol"},{"issue":"22","key":"7945_CR39","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","volume":"391","author":"PM Ridker","year":"2024","unstructured":"Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE. Inflammation, Cholesterol, Lipoprotein(a), and 30-year cardiovascular outcomes in women. N Engl J Med. 2024;391(22):2087\u201397.","journal-title":"N Engl J Med"},{"issue":"4","key":"7945_CR40","first-page":"844","volume":"19","author":"D Sehayek","year":"2025","unstructured":"Sehayek D, Cole J, Bj\u00f6rnson E, Wilkins JT, Mortensen MB, Dufresne L, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. J Clin Lipidol. 2025;19(4):844\u201359.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"7945_CR41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1046\/j.1538-7836.2003.00087.x","volume":"1","author":"S Grgurevich","year":"2003","unstructured":"Grgurevich S, Krishnan R, White MM, Jennings LK. Role of in vitro cholesterol depletion in mediating human platelet aggregation. J Thromb Haemost. 2003;1(3):576\u201386.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"7945_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11845-014-1102-7","volume":"184","author":"AA Seif","year":"2015","unstructured":"Seif AA. Chromium picolinate inhibits cholesterol-induced stimulation of platelet aggregation in hypercholesterolemic rats. Ir J Med Sci. 2015;184(2):291\u20136.","journal-title":"Ir J Med Sci"},{"issue":"5","key":"7945_CR43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bcp.12543","volume":"79","author":"JA Hirst","year":"2015","unstructured":"Hirst JA, Farmer AJ, Feakins BG, Aronson JK, Stevens RJ. Quantifying the effects of diuretics and \u03b2-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;79(5):733\u201343.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"7945_CR44","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1524-6175.2005.04679.x","volume":"8","author":"PA Sarafidis","year":"2006","unstructured":"Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich). 2006;8(5):351\u20136.","journal-title":"J Clin Hypertens (Greenwich)."},{"key":"7945_CR45","doi-asserted-by":"publisher","first-page":"f6008","DOI":"10.1136\/bmj.f6008","volume":"347","author":"HY Wu","year":"2013","unstructured":"Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347:f6008.","journal-title":"BMJ"},{"issue":"6","key":"7945_CR46","doi-asserted-by":"publisher","first-page":"e0326580","DOI":"10.1371\/journal.pone.0326580","volume":"20","author":"A Carazo","year":"2025","unstructured":"Carazo A, Pacl\u00edkov\u00e1 M, Fadraersada J, Alva-Gallegos R, Sko\u0159epa P, Gunaseelan C, et al. Type 1 diabetes mellitus patients had lower total vitamin K levels and increased sensitivity to direct anticoagulants. PLoS ONE. 2025;20(6):e0326580.","journal-title":"PLoS ONE"},{"issue":"20","key":"7945_CR47","doi-asserted-by":"publisher","first-page":"11170","DOI":"10.3390\/ijms222011170","volume":"22","author":"P Theofilis","year":"2021","unstructured":"Theofilis P, Sagris M, Antonopoulos AS, Oikonomou E, Tsioufis C, Tousoulis D. Inflammatory mediators of platelet activation: focus on atherosclerosis and COVID-19. Int J Mol Sci. 2021;22(20):11170.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"7945_CR48","first-page":"e256","volume":"32","author":"A Saeed","year":"2025","unstructured":"Saeed A, Haider M, Yousuf S, Ahmad S, Fine M, Yazdani A, et al. Role of proton pump inhibitors in prevention of upper gastrointestinal bleeding in patients on dual antiplatelet therapy: systematic review and meta-analysis. Am J Ther. 2025;32(3):e256\u201361.","journal-title":"Am J Ther"},{"issue":"3","key":"7945_CR49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ajh.2830170310","volume":"17","author":"HI Saba","year":"1984","unstructured":"Saba HI, Saba SR, Morelli GA. Effect of heparin on platelet aggregation. Am J Hematol. 1984;17(3):295\u2013306.","journal-title":"Am J Hematol"},{"issue":"4","key":"7945_CR50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.thromres.2004.09.004","volume":"115","author":"RF Storey","year":"2005","unstructured":"Storey RF, May JA, Heptinstall S. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin. Thromb Res. 2005;115(4):301\u20137.","journal-title":"Thromb Res"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-026-07945-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-026-07945-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-026-07945-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:05:06Z","timestamp":1791907506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12877-026-07945-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7945"],"URL":"https:\/\/doi.org\/10.1186\/s12877-026-07945-2","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was done in accordance with the Declaration of Helsinki, and approval was obtained from the Research ethics committee, Faculty of Pharmacy in Hradec Kr\u00e1lov\u00e9, Charles University (No. UKFaF\/92240\/2021\u20132 from March 3, 2021) and the Ethics committee of the University Hospital in Hradec Kr\u00e1lov\u00e9 (No. 202207 IO4 from 1 July 2022) before the start of the study, which ran from October 5, 2022 to December 10, 2024. Informed consent was obtained from each patient. In addition to a signed informed consent, relevant patient data (age, weight, height, smoking status, diagnoses, and medication) were recorded and anonymized.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1292"}}